Apellis Pharmaceuticals (APLS) Gets a Hold From Mizuho Securities
Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan
Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $39 From $42
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
J.P. Morgan analyst Anupam Rama maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $64 to $57.According to TipRanks data, the analyst has a success
Sobi and Enable Injections Announce Agreement to Develop and Distribute Aspaveli in Combination With EnFuse in Sobi Territories
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $66 to $61.According to TipRanks data, the analyst has a
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Profit Outlook
JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $64
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $64
J.P. Morgan analyst Anupam Rama maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and sets the target price at $64.According to TipRanks data, the analyst has a success rate of 45.7%
Express News | Apellis Pharmaceuticals Inc : JP Morgan Cuts Target Price to $64 From $72
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)
Express News | Apellis Pharmaceuticals Inc : UBS Cuts Target Price to $83 From $85
Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Mizuho Adjusts Apellis Pharmaceuticals' PT to $42 From $40, Keeps Neutral Rating
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target